Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

This content is for healthcare professionals only.

Please confirm you are a healthcare professional.

Yes
No
TEXAS VIRTUAL MPN WORKSHOP: Module III

Myelofibrosis

Presentations
To JAKi or not to JAKi How I treat ”Early” MF
Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
27 August, 2020
Ruxolitinib in 2020 and Beyond: The good, the suboptimal, and the failure
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH
27 August, 2020
Fedratinib
Claire Harrison, MD, FRCP, FRCPath, Guy's and St Thomas' NHS Foundation Trust, London, UK
27 August, 2020
Pacritinib
John Mascarenhas, MD, Mount Sinai, New York, NY
27 August, 2020
Momelotinib, Clinical Experience
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, KS
27 August, 2020
Previous session View all sessions Next session

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals